ArticleWorld journal of surgical oncology2026
An integrated analysis of MEN1 reveals its associations with clinical outcomes, cellular pathways, and the immune microenvironment.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The menin protein, encoded by the Multiple Endocrine Neoplasia Type 1 (MEN1) gene, serves as a critical regulator of cellular processes in human cancers. While menin-targeted therapies are undergoing clinical investigation, a comprehensive pan-cancer analysis of MEN1's diagnostic, prognostic, and immunomodulatory roles remain lacking. Here, we systematically evaluated MEN1 expression patterns and clinical relevance using multi-omics databases and immunohistochemical profiles from the Human Protein Atlas (HPA). MEN1 exhibited ubiquitous expression in normal tissues but was frequently upregulated across multiple malignancies, correlating with adverse survival outcomes. Elevated MEN1 expression demonstrated strong diagnostic utility and positive associations with tumor mutation burden (TMB), suggesting complementary value in cancer detection. Immune landscape analysis revealed significant correlations between MEN1 expression and immune checkpoint genes, as well as immune cell infiltration patterns. Functional characterization implicated MEN1 in activating cell cycle progression, DNA damage response, and oncogenic signaling pathways, as validated through Gene Set Enrichment Analysis (GSEA) and single-sample Gene Set Enrichment Analysis (ssGSEA). These findings position MEN1 as a promising prognostic biomarker and therapeutic target with implications for immuno-oncology and precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.